Revue medicale de Liege

An overview of tirzepatide studies for type 2 diabetes and obesity

GLP-1 Therapies Weekly Brief ↗PubMed ↗

Updated

Abstract

Tirzepatide, administered as a once-weekly injection, demonstrated a greater reduction in HbA1c and body weight compared to placebo and other treatments in six studies of the SURPASS programme.

  • The effectiveness of tirzepatide was observed in a dose-dependent manner at 5, 10, and 15 mg.
  • In the SURMOUNT programme, tirzepatide resulted in unprecedented weight loss among individuals with obesity or overweight and associated complications.
  • Weight loss with tirzepatide was linked to improvements in comorbidities such as sleep apnea syndrome and cardiovascular risk factors.
  • Two large cardiovascular outcome trials are currently assessing tirzepatide's safety and efficacy in patients with type 2 diabetes and obesity.

Simplified

Related papers

Aug '22
Tirzepatide’s effects on blood sugar control in type 2 diabetes
cited by 1 paper
randomized controlled trial
Jan '23
New developments in medicines targeting two gut hormones for treating type 2 diabetes
top 30% journal
cited by 55 papers
journal article
Feb '24
Simulated blood sugar and weight loss changes when switching weekly diabetes medication from semaglutide or dulaglutide to tirzepatide
top 30% journal
cited by 6 papers
journal article
Sep '22
Tirzepatide, a medicine targeting two hormone receptors, may better control blood sugar and reduce weight in type 2 diabetes
top 2% journal
cited by 296 papers
research support, non-u.s. gov't
Feb '24
Tirzepatide and its use in type 2 diabetes
top 2% journal
cited by 43 papers
journal article
Nov '21
Tirzepatide, a new medicine that activates two blood sugar hormones, as a potential heart and metabolism treatment
top 2% journal
cited by 106 papers
journal article
Dec '24
Tirzepatide for managing overweight and obesity
top 30% journal
cited by 20 papers
journal article
Dec '22
Reaching blood sugar goals with weight loss and no low blood sugar using the once-weekly drug tirzepatide in type 2 diabetes
cited by 33 papers
randomized controlled trial
Feb '24
Tirzepatide as a new heart-protecting treatment for type 2 diabetes and obesity
cited by 21 papers
journal article
Feb '23
Effectiveness and Safety of Tirzepatide for Managing Type 2 Diabetes and Obesity
top 5% journal
cited by 101 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief